Does insulin glarin (lantus) lead to a progression in diabetic retinopathy?;Führt insulin glargin (lantus) zu einer progression der diabetischen retinopathie?

Klinische Monatsblatter fur Augenheilkunde

Volumn 222, Issue 4, 2005, Pages 353-354

  Meyer, Carsten H ^a   Kroll, P ^a   Hammes, H P ^b  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN GLARGINE; ISOPHANE INSULIN; OCTREOTIDE; SOMATOMEDIN C; VASCULOTROPIN;

DIABETES MELLITUS; DIABETIC RETINOPATHY; EDITORIAL; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; RETINA CAPILLARY; RISK FACTOR;

CLINICAL TRIALS, PHASE IV; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; DISEASE PROGRESSION; HUMANS; INSULIN; INSULIN, ISOPHANE; INSULIN-LIKE GROWTH FACTOR I; RETINAL DISEASES; RETINAL VESSELS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 19744374381     PISSN: 00232165     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-858075     Document Type: Editorial

References (17)

1. Bolli GB, Owens DR. Insulin glargine. Lancet 2005; 356: 443-445
2. Rosak C. Insulinanaloga: Struktur, Eigenschaft und therapeutische Indikationen. Internist 2001; 42: 1692-1699
3. Lam S. Insulin glargine: a new once-daily basal insulin for the management of type 1 and type 2 diabetes mellitus. Heart Dis 2003; 5: 231-240
4. Rosenstock J, Park G, Zimmerman J. U.S. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Diabetes Care 2000; 23: 1137-1142
5. Luzio SD, Beck P, Owens DR. Comparison of the subcutaneous absorption of insulin glargine (Lantus) and NPH insulin in patients with Type 2 diabetes. Horm Metab Res 2003; 35: 434-438
6. Smith LE, Shen W, Perruzzi C et al. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 factor. Nat Med. 1999; 5(12): 1390-1395
7. Knott RM. Insulin-like growth factor type 1 friend or foe? Br J Ophthalmol 1998; 82: 719-721
8. Danis RP, Bingaman DP. Insulin-like growth factor-1 retinal microangiopathy in pig eyes. Ophthalmolohy 1997; 104: 1661-1669
9. Rubelte J, Ayuso E, Navarro M et al. Increased ocular levels of IGF-1 in transgenic mice lead to diabetes-like eye disease. J Clin Invest 2004; 113: 1149-1157
10. Chantelau E. Evidence that upregulation of serum IGF-1 concentration can trigger acceleration of diabetic retinopathy. Br J Ophthalmol 1998; 82: 725-730
11. Lang GE. Therapie der diabetischen Retinopathie mit Somatostatinanaloga. Ophthalmologe 2004; 101: 290-293
12. Arzneimittelkommission der deutschen Ärzteschaft. Glaskörper- und Retinablutungen unter Insulin Glargin. Deutsches Ärzteblatt 2002; 99: 727
13. Hauner H. Insulin gargin - das erste lang wirkende Insulinanalogon. Deutsches Ärzteblatt 2003; 100: 2508-2513
14. Eye disease prevalence research group. The prevalence of diabetic retinopahty among adults in the United states. Arch Ophthalmol 2004; 122: 552-563
15. Hammes HP. Pathophysiological mechanisms of diabetic angiopathy. J Diabetes Complications 2003; 17 (2 Suppl): 16-19
16. Diabetes Control and Complications trial (DCCT) Research group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Eng J Med 1993; 329: 977-986
17. Hörle S, Gruner F, Kroll P. Epidemiologie der diabetischen Blindheit - eine Übersicht. Klin Monatsbl Augenheilkd 2002; 219: 777-784